Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Urology
Published in: BMC Urology 1/2017

Open Access 01-12-2017 | Research article

Canadian Men’s perspectives about active surveillance in prostate cancer: need for guidance and resources

Authors: Margaret Fitch, Kittie Pang, Veronique Ouellet, Carmen Loiselle, Shabbir Alibhai, Simone Chevalier, Darrel E. Drachenberg, Antonio Finelli, Jean-Baptiste Lattouf, Simon Sutcliffe, Alan So, Simon Tanguay, Fred Saad, Anne-Marie Mes-Masson

Published in: BMC Urology | Issue 1/2017

Login to get access

Abstract

Background

In prostate cancer, men diagnosed with low risk disease may be monitored through an active surveillance. This research explored the perspectives of men with prostate cancer regarding their decision-making process for active surveillance to identify factors that influence their decision and assist health professionals in having conversations about this option.

Methods

Focus group interviews (n = 7) were held in several Canadian cities with men (N = 52) diagnosed with prostate cancer and eligible for active surveillance. The men’s viewpoints were captured regarding their understanding of active surveillance, the factors that influenced their decision, and their experience with the approach. A content and theme analysis was performed on the verbatim transcripts from the sessions.

Results

Patients described their concerns of living with their disease without intervention, but were reassured by the close monitoring under AS while avoiding harmful side effects associated with treatments. Conversations with their doctor and how AS was described were cited as key influences in their decision, in addition to availability of information on treatment options, distrust in the health system, personality, experiences and opinions of others, and personal perspectives on quality of life.

Conclusions

Men require a thorough explanation on AS as a safe and valid option, as well as guidance towards supportive resources in their decision-making.
Literature
1.
Raldow AC, Zhang D, Chen MH, Braccioforte MH, Moran BJ, D’Amico AV. Risk group and death from prostate cancer: implications for active surveillance in men with favorable intermediate-risk prostate cancer. JAMA Oncol. 2015;1(3):334–40.CrossRefPubMed
2.
Sternberg IA, Vela I, Scardino PT. Molecular profiles of prostate cancer: to treat or not to treat. Annu Rev Med. 2016;67:119–35.CrossRefPubMed
3.
4.
Bruinsma SM, Bangma CH, Carroll PR, Leapman MS, Rannikko A, Petrides N, Weerakoon M, Bokhorst LP, Roobol MJ, Movember GAPc. Active surveillance for prostate cancer: a narrative review of clinical guidelines. Nat Rev Urol. 2016;13(3):151–67.CrossRefPubMed
5.
Tosoian JJ, Carter HB, Lepor A, Loeb S. Active surveillance for prostate cancer: current evidence and contemporary state of practice. Nat Rev Urol. 2016;13(4):205–15.CrossRefPubMedPubMedCentral
6.
Dinh KT, Mahal BA, Ziehr DR, Muralidhar V, Chen YW, Viswanathan VB, Nezolosky MD, Beard CJ, Choueiri TK, Martin NE, et al. Incidence and predictors of upgrading and up staging among 10,000 contemporary patients with low risk prostate cancer. J Urol. 2015;194(2):343–9.CrossRefPubMed
7.
Ting F, van Leeuwen PJ, Delprado W, Haynes AM, Brenner P, Stricker PD. Tumor volume in insignificant prostate cancer: increasing the threshold is a safe approach to reduce over-treatment. Prostate. 2015;75(15):1768–73.CrossRefPubMed
8.
Timilshina N, Ouellet V, Alibhai SM, Mes-Masson AM, Delvoye N, Drachenberg D, Finelli A, Jammal MP, Karakiewicz P, Lapointe H, et al. Analysis of active surveillance uptake for low-risk localized prostate cancer in Canada: a Canadian multi-institutional study. World J Urol. 2016;35(4):595-03.
9.
Thorne S. Data analysis in qualitative research. Evid Based Nurs. 2000;3:68–70.CrossRef
10.
Glaser AP, Novakovic K, Helfand BT. The impact of prostate biopsy on urinary symptoms, erectile function, and anxiety. Curr Urol Rep. 2012;13(6):447–54.CrossRefPubMed
11.
Kazer MW, Psutka SP, Latini DM, Bailey DE Jr. Psychosocial aspects of active surveillance. Curr Opin Urol. 2013;23(3):273–7.PubMed
12.
Volk RJ, McFall SL, Cantor SB, Byrd TL, Le YC, Kuban DA, Mullen PD. It’s not like you just had a heart attack’: decision-making about active surveillance by men with localized prostate cancer. Psychooncology. 2014;23(4):467–72.CrossRefPubMed
13.
van den Bergh RC, Korfage IJ, Bangma CH. Psychological aspects of active surveillance. Curr Opin Urol. 2012;22(3):237–42.CrossRefPubMed
14.
Venderbos LD, van den Bergh RC, Roobol MJ, Schroder FH, Essink-Bot ML, Bangma CH, Steyerberg EW, Korfage IJ. A longitudinal study on the impact of active surveillance for prostate cancer on anxiety and distress levels. Psychooncology. 2015;24(3):348–54.CrossRefPubMed
15.
van den Bergh RC, van Vugt HA, Korfage IJ, Steyerberg EW, Roobol MJ, Schroder FH, Essink-Bot ML. Disease insight and treatment perception of men on active surveillance for early prostate cancer. BJU Int. 2010;105(3):322–8.CrossRefPubMed
16.
de Bekker-Grob EW, Bliemer MC, Donkers B, Essink-Bot ML, Korfage IJ, Roobol MJ, Bangma CH, Steyerberg EW. Patients’ and urologists’ preferences for prostate cancer treatment: a discrete choice experiment. Br J Cancer. 2013;109(3):633–40.CrossRefPubMedPubMedCentral
17.
Hurwitz LM, Cullen J, Elsamanoudi S, Kim DJ, Hudak J, Colston M, Travis J, Kuo HC, Porter CR, Rosner IL. A prospective cohort study of treatment decision-making for prostate cancer following participation in a multidisciplinary clinic. Urol Oncol. 2015;34(5):233.e17-25.
18.
Davison BJ, Goldenberg SL. Patient acceptance of active surveillance as a treatment option for low-risk prostate cancer. BJU Int. 2011;108(11):1787–93.CrossRefPubMed
19.
Davison BJ, Breckon E. Factors influencing treatment decision making and information preferences of prostate cancer patients on active surveillance. Patient Educ Couns. 2012;87(3):369–74.CrossRefPubMed
20.
21.
O’Callaghan C, Dryden T, Hyatt A, Brooker J, Burney S, Wootten AC, White A, Frydenberg M, Murphy D, Williams S, et al. ‘What is this active surveillance thing?’ Men’s and partners’ reactions to treatment decision making for prostate cancer when active surveillance is the recommended treatment option. Psychooncology. 2014;23(12):1391–8.CrossRefPubMed
22.
Orom H, Homish DL, Homish GG, Underwood W 3rd. Quality of physician-patient relationships is associated with the influence of physician treatment recommendations among patients with prostate cancer who chose active surveillance. Urol Oncol. 2014;32(4):396–402.CrossRefPubMed
23.
Tombal B, Baskin-Bey E, Schulman C. Access to information and expectations of treatment decisions for prostate cancer patients--results of a European survey. Eur J Cancer Care (Engl). 2013;22(2):210–8.CrossRef
24.
Mishra MV, Bennett M, Vincent A, Lee OT, Lallas CD, Trabulsi EJ, Gomella LG, Dicker AP, Showalter TN. Identifying barriers to patient acceptance of active surveillance: content analysis of online patient communications. PLoS One. 2013;8(9):e68563.CrossRefPubMedPubMedCentral
25.
Dogan C, Gultekin HM, Erdogan SM, Ozkara H, Talat Z, Erozenci AN, Obek C. Patient decision making prior to radical prostatectomy: what is and is not involved. Am J Mens Health. 2015. Epub ahead of print.
26.
Anandadas CN, Clarke NW, Davidson SE, O’Reilly PH, Logue JP, Gilmore L, Swindell R, Brough RJ, Wemyss-Holden GD, Lau MW, et al. Early prostate cancer--which treatment do men prefer and why? BJU Int. 2011;107(11):1762–8.CrossRefPubMed
27.
Devos J, Van Praet C, Decaestecker K, Claeys T, Fonteyne V, Decalf V, De Meerleer G, Ost P, Lumen N. Cognitive factors influencing treatment decision-making in patients with localised prostate cancer: development of a standardised questionnaire. Acta Clin Belg. 2015;70(4):272–9.CrossRefPubMed
28.
Simpkin AJ, Tilling K, Martin RM, Lane JA, Hamdy FC, Holmberg L, Neal DE, Metcalfe C, Donovan JL. Systematic review and meta-analysis of factors determining change to radical treatment in active surveillance for localized prostate cancer. Eur Urol. 2015;67(6):993–1005.CrossRefPubMed
29.
Chabrera C, Font A, Caro M, Areal J, Zabalegui A. Developing a decision aid to support informed choices for newly diagnosed patients with localized prostate cancer. Cancer Nurs. 2015;38(1):E55–60.CrossRefPubMed
30.
Adsul P, Wray R, Spradling K, Darwish O, Weaver N, Siddiqui S. Systematic review of decision aids for newly diagnosed patients with prostate cancer making treatment decisions. J Urol. 2015;194(5):1247–52.CrossRefPubMed
31.
Lin GA, Aaronson DS, Knight SJ, Carroll PR, Dudley RA. Patient decision aids for prostate cancer treatment: a systematic review of the literature. CA Cancer J Clin. 2009;59(6):379–90.CrossRefPubMed
32.
Violette PD, Agoritsas T, Alexander P, Riikonen J, Santti H, Agarwal A, Bhatnagar N, Dahm P, Montori V, Guyatt GH, et al. Decision aids for localized prostate cancer treatment choice: systematic review and meta-analysis. CA Cancer J Clin. 2015;65(3):239–51.CrossRefPubMed
Metadata
Title
Canadian Men’s perspectives about active surveillance in prostate cancer: need for guidance and resources
Authors
Margaret Fitch
Kittie Pang
Veronique Ouellet
Carmen Loiselle
Shabbir Alibhai
Simone Chevalier
Darrel E. Drachenberg
Antonio Finelli
Jean-Baptiste Lattouf
Simon Sutcliffe
Alan So
Simon Tanguay
Fred Saad
Anne-Marie Mes-Masson
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2017
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/s12894-017-0290-7

Other articles of this Issue 1/2017

BMC Urology 1/2017 Go to the issue

Research article

Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma

Erratum

Erratum to: Patient preferences for treatment of castration-resistant prostate cancer in Japan: a discrete-choice experiment

Research article

The neutrophil-to-lymphocyte ratio (NLR) predicts adrenocortical carcinoma and is correlated with the prognosis

Research article

Do men regret prostate biopsy: Results from the PiCTure study

Review

miRNAs associated with prostate cancer risk and progression

Research article

Increasing bladder capacity by foot stimulation in rats with spinal cord injuries